Private equity majors circle $9bn-valued Parexel as Pamplona Capital mulls exit options

Contract research firm Parexel is said to garner takeover interest from Private equity giant EQT and a consortium of three other buyout majors.

A consortium of Cinven, Centerbridge and GTCR is working on a bid for the contract research organization, according to traders, who cited a Bloomberg report.

Parexel is said to have received interest from about 10 parties.

Bloomberg reported in April Parexel’s PE owner Pamplona Capital Management was exploring a sale of the company in a deal that could value Parexel at about $9B including debt.

The potential sale comes after some other big deals for CROs earlier this year including Thermo Fisher’s (NYSE:TMO) planned $17B deal for PPD (NASDAQ:PPD) and Icon PLC’s agreement to purchase PRA Health (NASDAQ:PRAH) for about $12B.

Source: Seeking Alpha